Therapeutic Gains of Prolonged Bronchial Dilatation in Chronic Obstructive Pulmonary Disease
G. Turino
DOI: https://doi.org/10.7326/0003-4819-143-5-200509060-00014
IF: 39.2
2005-09-06
Annals of Internal Medicine
Abstract:Chronic obstructive pulmonary disease (COPD) is a major global medical problem. In the United States, COPD causes more than 500000 hospitalizations and 100000 deaths per year (1, 2). As many as 25 million individuals are estimated to have various stages of COPD in the United States (3). The definition of COPD, which resulted from a National Heart, Lung, and Blood Institute and World Health Organization conference, is a disease state characterized by airflow obstruction that is not fully reversible. The airflow obstruction is usually both progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases (4). The clinical spectrum of COPD includes chronic bronchitis, emphysema, and refractory asthma. In most patients with advanced disease, each of these disorders may be present but in variable proportions. There is also an awareness of the need to include variables such as body mass index, dyspnea, and exercise capacity in categorizing patients with COPD, along with spirometric measurements (5). However, as indicated, the major manifestation of COPD, regardless of the variable diagnostic components, is airway obstruction. Another important feature, and a significant factor in the clinical course of patients with COPD, is the occurrence of clinical exacerbations (6). Exacerbations that occur with a usual frequency of 1 to 3 events per patient per year result in a more rapid decrease in lung function but also substantially affect quality of life and the economic cost of COPD (7, 8). In this issue, Niewoehner and colleagues' report (9) of a multicenter, large cohort study takes on added importance because of these considerations and therapeutic approaches for COPD. The 6-month study demonstrated that once-daily use of the long-acting anticholinergic bronchodilator tiotropium, when compared with placebo, statistically significantly reduced the percentage of patients experiencing 1 or more exacerbations from 32% to 28%. Also, fewer tiotropium-treated patients were hospitalized due to exacerbations of COPD (7.7% vs. 9.5%), which was borderline statistically significant (P= 0.056). Secondary outcomes indicate that tiotropium may lengthen the time to first COPD exacerbation and may require fewer health care interventions, such as frequency of hospitalization, antibiotic use, and unscheduled clinic visits. A major strength of Niewoehner and colleagues' study is the large number of patients recruited (n= 1829), with a relatively uniform classification of moderate to severe disease. The mean baseline prebronchodilator FEV1 was 36% of predicted. Twenty-six veterans' health centers participated to achieve this large number of participants. The study was double-blind and placebo-controlled. A limitation of the study was that the patients were all men in a single health care system. Niewoehner and colleagues used a rigorous, practical definition of an exacerbation: more than 1 of a complex of respiratory symptoms (increase or new-onset)cough, sputum, wheezing, dyspnea, or chest tightnesslasting at least 3 days and requiring antibiotic treatment, steroid treatment, or hospitalization. The test medication, tiotropium, is a long-acting anticholinergic agent that has been shown to increase FEV1 and inspiratory capacity for 24 hours after 1 dose (10-12). Increased cholinergic tone mediated through the vagus nerve is a clinically significant factor in bronchial obstruction in COPD, and anticholinergic therapy is beneficial. Tiotropium induces sustained bronchial dilatation by its prolonged muscarinic M3 receptor antagonism so that 1 inhaled dose of 18 g produces bronchodilatation for 24 hours (10). Use of the drug has been associated with symptomatic improvement, reduction in hyperinflation of the lung, and reduction in dyspnea (13, 14). Niewoehner and colleagues' study adds confirmatory data to those reported by Casaburi and colleagues (15) and Vincken and colleagues (16). Both studies showed a reduction in exacerbations in patients followed for 1 year while receiving daily tiotropium. Exacerbations were reduced by 24% in Vincken and colleagues' study and by 30% in Casaburi and colleagues' study. In both studies, tiotropium improved the symptoms of shortness of breath and wheezing, compared with placebo (15) or ipratropium (16). A question should be addressed from these studies: What are the mechanisms by which long-acting bronchodilators can produce beneficial effects on exacerbations? Possibilities include improved bronchial mucociliary clearance, which could reduce the potential for increased bacterial colonization or acute infections with new bacterial pathogens. Bronchodilatation may produce more effective clearance by cough or a reduced state of inflammation because of reduced hyperinflation, recognizing that hyperinflation itself may lead to tissue injury. Hyperinflation increases lung residual volume and imposes the factors of matrix and cellular stretch. Prolonged airway obstruction through tissue stretch may therefore set up mechanical forces in the airway and surrounding alveolar structures, which impose cellular and cytokine responses that are proinflammatory and initiate or magnify bronchial smooth-muscle reactivity (17, 18). In this regard, studies have suggested that proinflammatory cytokines are increased in ventilator-induced lung injury and may be elevated by overdistention of lung tissue (19). Microarray analysis of human lung epithelial cells has shown that cycling mechanical stretch alone profoundly affects gene expression (17, 20). The percentage of reductions in exacerbations and hospitalizations reported in Niewoehner and colleagues' study (9) may seem modest. However, when viewed from the perspective of a worldwide population of patients with COPD (21), the clinical and economic benefits of effective bronchodilator therapy are meaningful. Tiotropium should rightfully be considered a first-line medication in therapy for COPD, and long-term studies longer than 1 year, as already reported (22), may indicate that prolonged reduction of bronchial obstruction may lessen the annual decrease in lung function in patients with COPD over the long term. Physicians and health care workers who diagnose COPD and care for affected patients should be aware of the therapeutic potential of sustained bronchodilatation and apply effective bronchodilator therapy as a mainstay in a disease for which effective therapies are greatly needed.